Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis

American Journal of Therapeutics

Volumn 18, Issue 5, 2011, Pages 375-381

  Treeprasertsuk, Sombat ^a,b   Silveira, Marina G ^a   Petz, Janice L ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

bone disease; parenteral bisphosphonates; primary biliary cirrhosis; treatment

Indexed keywords

IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FEMALE; FEMUR; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; LUMBAR SPINE; MALE; MYALGIA; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES;

EID: 80052706885     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d7e1d3     Document Type: Article

References (24)

1. Menon KV, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001;35:316-323. (Pubitemid 32844184)
2. Newton J, Francis R, Prince M, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut. 2001;49:282-287. (Pubitemid 32675124)
3. Pares A, Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis. 2008; 12:407-424; x. (Pubitemid 351635892)
4. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46:1271-1278. (Pubitemid 350144791)
5. Guichelaar MM, Malinchoc M, Sibonga J, et al. Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Liver Transpl. 2004;10:638-647. (Pubitemid 38628224)
6. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
7. Mounach A, Ouzzif Z, Wariaghli G, et al. Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab. 2008;26:379-384. (Pubitemid 351950694)
8. Benetti A, Crosignani A, Varenna M, et al. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol. 2008;42:306-311. (Pubitemid 351301498)
9. Guichelaar MM, Kendall R, Malinchoc M, et al. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl. 2006;12: 1390-1402. (Pubitemid 44405129)
10. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42: 762-771. (Pubitemid 41401113)
11. Guanabens N, Pares A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2268-2274. (Pubitemid 37305369)
12. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003;125:941-966. (Pubitemid 37070710)
13. Reeves HL, Francis RM, Manas DM, et al. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg. 1998;4:404-409. (Pubitemid 28413242)
14. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291-308.
15. Floreani A, Carderi I, Ferrara F, et al. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. Dig Liver Dis. 2007;39:544-548. (Pubitemid 46746645)
16. Ringe JD, Kipshoven C, Coster A, et al. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int. 1999;9: 171-178. (Pubitemid 29219080)
17. Guichelaar MM, Schmoll J, Malinchoc M, et al. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology. 2007;46:1198-1207. (Pubitemid 350144784)
18. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548-1558. (Pubitemid 47500128)
19. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther. 2005;27:361-376. (Pubitemid 40732645)
20. Abitbol V, Briot K, Roux C, et al. A double-blind placebocontrolled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:1184-1189. (Pubitemid 47496232)
21. Boone RH, Cheung AM, Girlan LM, et al. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci. 2006;51:1103-1112. (Pubitemid 44127061)
22. Levy C, Harnois DM, Angulo P, et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005;25: 117-121. (Pubitemid 40298253)
23. Ormarsdottir S, Mallmin H, Naessen T, et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med. 2004;256: 63-69. (Pubitemid 38813621)
24. Lindor KD, Jorgensen RA, Tiegs RD, et al. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol. 2000;33:878-882.